Amylyx Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Amylyx Pharmaceuticals' average stock price target increased from $42.36 to $43, according to 11 analysts, with a range of $20 to $57. This implies 59% upside from the Oct. 14 closing price. The consensus rating remains 'Buy' among 12 analysts.
MILNE GEORGE M JR sold 30,000 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at $27.70 ($0.83M total) on 2026-10-05 under a Rule 10b5-1 trading plan.
Amylyx Pharmaceuticals, Inc. has a lock-up agreement for certain restricted stock units ending on 4-OCT-2026. The company, its officers, and directors agreed not to dispose of or hedge shares for 45 days post-prospectus supplement, except with consent from Leerink Partners, Morgan Stanley, and Guggenheim Securities. Amylyx focuses on investigational therapies, including avexitide for hypoglycemia and AMX0035 for neurodegeneration.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AMLX (Amylyx Pharmaceuticals, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent AMLX coverage spans financial news, insider activity and corporate actions.
In the last 30 days, AMLX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($831K). The most active reporter was MILNE GEORGE M JR with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Higher consensus price targets can support near-term sentiment, but the piece is purely analyst-target movement with no new company fundamentals.
The insider sale modestly increases supply pressure on AMLX shares.
Amylyx Pharmaceuticals, Inc. has a lock-up agreement for certain restricted stock units ending on 4-OCT-2026. The company, its officers, and directors agreed not to dispose of or hedge shares for 45 days post-prospectus supplement, except with consent from Leerink Partners, Morgan Stanley, and Guggenheim Securities. Amylyx focuses on investigational therapies, including avexitide for hypoglycemia and AMX0035 for neurodegeneration.
Positive trial data may drive the stock higher as investors anticipate regulatory approval and commercial launch.
Analyst upgrades and positive trial data suggest upward pressure on AMLX.
AlphAI scores every news story that mentions AMLX with an AI model for sentiment and relevance, and aggregates insider trades from Amylyx Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Amylyx Pharmaceuticals' average stock price target increased from $42.36 to $43, according to 11 analysts, with a range of $20 to $57. This implies 59% upside from the Oct. 14 closing price. The consensus rating remains 'Buy' among 12 analysts.
1 min readMILNE GEORGE M JR sold 30,000 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at $27.70 ($0.83M total) on 2026-10-05 under a Rule 10b5-1 trading plan.
1 min readAmylyx Pharmaceuticals, Inc. has a lock-up agreement for certain restricted stock units ending on 4-OCT-2026. The company, its officers, and directors agreed not to dispose of or hedge shares for 45 days post-prospectus supplement, except with consent from Leerink Partners, Morgan Stanley, and Guggenheim Securities. Amylyx focuses on investigational therapies, including avexitide for hypoglycemia and AMX0035 for neurodegeneration.
1 min readAmylyx Pharmaceuticals reported positive Phase III results for avexitide in treating PBH, with plans to file for FDA approval by year-end. The company estimates 160,000 U.S. patients with PBH, with 120,000 following Roux-en-Y gastric bypass. Management is preparing for a potential 2024 or 2027 launch, depending on the FDA label. Amylyx is also developing AMX0318 for PBH, targeting an IND filing next year.
2 min readStifel maintained a Buy rating and $45 price target for Amylyx (AMLX), citing confidence in avexitide's Phase 3 data and commercial potential. The stock is up 141% YTD. Other analysts raised price targets post-trial results, with a consensus Strong Buy rating. Avexitide showed a 55% reduction vs. placebo in the LUCIDITY trial.
2 min readAmylyx Pharmaceuticals (AMLX) secured long-term supply agreements for avexitide, including a $30M upfront fee. The deals indicate commitment to commercialization but depend on LUCIDITY Phase III trial success. Analysts forecast $343.4M revenue and $86.8M earnings by 2029, with potential 31% upside. Management will discuss plans at a conference in September 2026.
3 min readAmylyx Pharmaceuticals (AMLX) shares fell as investors took profits after a rally driven by positive Phase 3 data for avexitide. Concerns include valuation, dilution from a $500M stock offering, and insider sales. The company faces high funding needs for commercialization around 2027, shifting focus to financial costs and capital access.
2 min readAmylyx Pharmaceuticals' co-founder Joshua Cohen sold $950k worth of stock at $32.16 per share, reducing his holding by 0.9%. This was the largest insider sale in the past year, occurring below the current price of $33.15. Insiders have sold more shares than bought over the past year, with total insider ownership at 6.2% of the company.
1 min readAmylyx Pharmaceuticals (AMLX) shares declined after a Morgan Stanley event, retreating from 52-week highs. Investors reassess valuation due to manufacturing commitments and capital needs for a 2027 drug launch. Recent rally and public offering raised scrutiny over funding strategy and execution risk. Long-term prospects depend on avexitide's success, but cash burn and reliance on equity offerings pose challenges.
2 min readBedrosian Camille L (Chief Medical Officer) sold 10,028 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $32.40 ($32.21–$33.09, $0.32M total) across 2 trades on 2026-09-10.
1 min read
